Citadel Advisors
ATRA icon

Citadel Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Citadel Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-208
Closed -$1.77K – 14214
2024
Q2 		$1.77K Sell
208
-1,844
-90% -$27.7K ﹤0.01% 13780
2024
Q1 		$35.6K Buy
2,052
+2,044
+25,550% +$36.3K ﹤0.01% 12511
2023
Q4 		$103 Sell
8
-1,876
-100% -$43.7K ﹤0.01% 14128
2023
Q3 		$69.7K Buy
1,884
+1,340
+246% +$59.6K ﹤0.01% 11332
2023
Q2 		$21.9K Buy
544
+316
+139% +$17.9K ﹤0.01% 12651
2023
Q1 		$16.5K Sell
228
-44
-16% -$4.27K ﹤0.01% 13197
2022
Q4 		$22.3K Buy
+272
New +$28.3K ﹤0.01% 13054
2022
Q1 		– Sell
-424
Closed -$167K – 13543
2021
Q4 		$167K Sell
424
-220
-34% -$92.6K ﹤0.01% 12120
2021
Q3 		$288K Sell
644
-448
-41% -$161K ﹤0.01% 11133
2021
Q2 		$425K Buy
1,092
+308
+39% +$110K ﹤0.01% 10419
2021
Q1 		$281K Sell
784
-44
-5% -$19.4K ﹤0.01% 11005
2020
Q4 		$406K Buy
828
+364
+78% +$168K ﹤0.01% 8536
2020
Q3 		$150K Sell
464
-8
-2% -$2.72K ﹤0.01% 9004
2020
Q2 		$172K Sell
472
-28
-6% -$7.07K ﹤0.01% 8642
2020
Q1 		$106K Sell
500
-452
-47% -$143K ﹤0.01% 8594
2019
Q4 		$392K Buy
952
+40
+4% +$13.8K ﹤0.01% 7181
2019
Q3 		$322K Buy
912
+452
+98% +$169K ﹤0.01% 7455
2019
Q2 		$231K Buy
+460
New +$325K ﹤0.01% 7983
2019
Q1 		– Sell
-428
Closed -$372K – 9233
2018
Q4 		$372K Sell
428
-644
-60% -$598K ﹤0.01% 6887
2018
Q3 		$1.11M Buy
1,072
+684
+176% +$669K ﹤0.01% 5351
2018
Q2 		$356K Sell
388
-224
-37% -$241K ﹤0.01% 6927
2018
Q1 		$597K Buy
+612
New +$558K ﹤0.01% 5599

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's ATRA Position: Q1 2026 in Review

Citadel Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 15,577 shares — an estimated $282K sold.

Citadel Advisors first reported a position in ATRA in Q3 2015 and held it in 31 quarters. The position peaked at $9.08M in Q3 2019. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Citadel Advisors reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 15,577 Atara Biotherapeutics shares in Q1 2026, an estimated $282K.
  • Citadel Advisors first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 31 quarters.
  • Citadel Advisors's Atara Biotherapeutics position peaked at $9.08M in Q3 2019.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.